car-t-cells

Documents about car-t-cells

• Temporal dynamics of immune effector cell‐associated haematotoxicity: Linking early and late cytopenias after chimeric antigen receptor T cells#1000656HAL (France)
• Successful Use of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy with Lisocabtagene Maraleucel in a Renal Transplant Recipient with Refractory/Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)#219205ODU Digital Commons
• CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)#283058ClinicalTrials.gov
• Stem Cells From Human Exfoliated Teeth in Treatment of Type 2 Diabetes#424298ClinicalTrials.gov
• Synovium-Restricted Armored PD-1-Targeted CAR-T Cells Reprogram Immunity and Resolve Experimental Arthritis#441652bioRxiv / medRxiv
• Engineering CAR-T cells for solid tumors: overcoming antigenic, trafficking, and microenvironmental barriers.#452934NCBI PubMed Central
• ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors#849953ClinicalTrials.gov
• Phase I Study of TX103 CAR-T Cells in Participants With Advanced Solid Tumors#859877ClinicalTrials.gov
• A Study of CAR-T Cells in Subjects With Autoimmune Diseases#982621ClinicalTrials.gov
• CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL#889283ClinicalTrials.gov
• CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia#912585ClinicalTrials.gov
• Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMM#1010948ClinicalTrials.gov
• GPC3/Mesothelin-CAR-γδT Cells Against Cancers#879860ClinicalTrials.gov
• Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.#890724ClinicalTrials.gov
• FIBROBLAST ACTIVATION PROTEIN+ STROMAL CELLS PROMOTE MACROPHAGE-MEDIATED IMMUNOSUPPRESSION AND LIMIT CAR-T CELL ACCUMULATION IN GLIOBLASTOMA#929313ScholarlyCommons
• Development of a flow cytometry method to measure antidrug antibodies against CAR T cells.#135927NCBI PubMed Central
• CARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia#249591ClinicalTrials.gov
• Study Investigating the Safety of CD19 CAR-T Cells in Relapsed/Refractory AML Expressing CD19#290966ClinicalTrials.gov
• REACT-01: Reversing Autoimmunity Through Cell Therapy#862740ClinicalTrials.gov
• GFRα4 CAR T Cells in MTC Patients#1030003ClinicalTrials.gov
• Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma#841981ClinicalTrials.gov
• Adaptive-like CAR-iPSC-CD4⁺ T cells outperform CD8⁺ counterparts in sustained ALL control#189741Kyoto University Research Information Repository
• Adaptive-like CAR-iPSC-CD4⁺ T cells outperform CD8⁺ counterparts in sustained ALL control#189780Kyoto University Research Information Repository
• To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL#824946ClinicalTrials.gov
• A Retrospective Study of Patients With Leukemia Relapse in the CNS Treated With CAR T Cells#28324ClinicalTrials.gov
• CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma#253055ClinicalTrials.gov
• CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy#290970ClinicalTrials.gov
• NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors#314341ClinicalTrials.gov
• CAR-T Cells in Treating Patients With Relapsed or Refractory NHL#346965ClinicalTrials.gov
• Immunotherapy With BCMA CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma#366578ClinicalTrials.gov
• Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary Lesions#454029ClinicalTrials.gov
• Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies#888254ClinicalTrials.gov
• A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma#882667ClinicalTrials.gov
• The clinical picture of ICANS after CAR-T cell therapy in critically ill patients: A retrospective clustering analysis of a multicentre multinational cohort study#669977HAL (France)
• CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies#363603ClinicalTrials.gov
• A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)#842983ClinicalTrials.gov
• A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)#907429ClinicalTrials.gov
• Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.#143367NCBI PubMed Central
• Mathematical modeling and sensitivity analysis of synNotch-CAR T-cells identify engineering targets for dynamic tunability#146485bioRxiv / medRxiv
• A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma#180388ClinicalTrials.gov
• Data Management and Sharing Plan for: SBIR: In vivo engineering of B7-H3.CAR-T cells for ovarian cancer therapy#207837UNC Dataverse Dataverse OAI Archive
• CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies#411402ClinicalTrials.gov
• Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial#432891ClinicalTrials.gov
• Invasive fungal infections after CD19 chimeric antigen receptor T-cell therapy for B-cell lymphoma: a Lymphoma study association study from the DESCAR-T (Dispositif d’Enregistrement et Suivi des patients traités par CAR-T cells) registry#239043HAL (France)
• GD2-CAR T Cells for Pediatric Brain Tumours#801382ClinicalTrials.gov
• A Study of MCARH109 and MCARH125 in People With Multiple Myeloma#899527ClinicalTrials.gov
• A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy#992506ClinicalTrials.gov
• CMV-specific HIV-CAR T Cells as Immunotherapy for HIV/AIDS#864012ClinicalTrials.gov
• Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas#158216ClinicalTrials.gov
• Allogeneic Second-generation CD19-CAR T Cells for Pediatric Relapsed/Refractory B-ALL#181600ClinicalTrials.gov